Sign In to Request a Protocol
Sign In to Request a Protocol

CJC-1295 DAC (5 mg Vial)

  • Table of Contents

CJC-1295 DAC Dosage Chart

CJC-1295 DAC is dosed at 300 mcg–1 mg weekly via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 2.5 mg/mL. This information is for research and educational use only.

  • Reconstitution: Add 2.0 mL of bacteriostatic water to achieve a concentration of 2.5 mg/mL (2,500 mcg/mL).
  • Typical Dose: 300–1,000 mcg per injection, administered twice weekly, with optional gradual titration depending on the planned protocol.
  • Measurement Guide: At a concentration of 2.5 mg/mL, 1 unit (0.01 mL) on a U-100 insulin syringe delivers 25 mcg.
  • Storage: Store lyophilized vials at −20 °C (−4 °F). After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and avoid repeated freeze–thaw cycles.
CJC-1295 DAC is a long-acting synthetic growth hormone-releasing hormone (GHRH) analog. Its Drug Affinity Complex (DAC) modification allows it to bind reversibly to albumin, extending its duration of action compared with CJC-1295 NO DAC. It works by stimulating GHRH receptors in the pituitary gland, helping promote the body’s natural release of growth hormone (GH) and supporting healthy IGF-1 activity over time. Due to its extended duration of action, CJC-1295 DAC is commonly studied using a twice-weekly subcutaneous administration schedule rather than daily dosing. This protocol uses a practical dilution designed to provide clear and consistent insulin syringe measurements. Note: Current evidence is based primarily on preclinical research and limited human studies. Additional clinical research is needed to further evaluate the safety and effectiveness of CJC-1295 DAC.
  • Dosing & Reconstitution Guide

Educational guide for reconstitution and twice-weekly dosing

Standard / Gradual Approach (2 mL = 2500 mcg/mL)

WeekPer-Injection Dose (mcg)Units (per injection) (mL)Weekly Total
Weeks 1–2300 mcg (0.3 mg)12 units (0.12 mL)600 mcg/week
Weeks 3–4500 mcg (0.5 mg)20 units (0.20 mL)1000 mcg/week
Weeks 5–6750 mcg (0.75 mg)30 units (0.30 mL)1500 mcg/week
Weeks 7–121000 mcg (1 mg)40 units (0.40 mL)2000 mcg/week
Administration: Inject twice weekly by subcutaneous injection (for example, Monday/Thursday or Tuesday/Friday). Dosing Schedule: Due to its extended duration of action, CJC-1295 DAC is commonly studied using a less frequent dosing schedule than non-DAC GHRH analogs. Some research protocols also evaluate once-weekly administration. Syringe Selection: For doses requiring 10 units (0.10 mL) or less, a 30-unit or 50-unit U-100 insulin syringe may provide easier and more accurate measurement.

Reconstitution Steps

  • Draw 2.0 mL of bacteriostatic water using a sterile syringe.
  • Inject the water slowly down the inside wall of the vial to help minimize foaming.
  • Gently swirl or roll the vial until the powder has completely dissolved. Do not shake the vial.
  • Label the vial with the reconstitution date and store it refrigerated at 2–8 °C (35.6–46.4 °F), protected from direct light.

Important: This guide is for educational purposes only and is not medical advice. This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

  • Supplies Needed

Plan based on an 8–16 week twice-weekly protocol with gradual titration.

  • Peptide Vials (CJC-1295 DAC, 5 mg each)
  • 8 weeks ≈ 3 vials (~10.2 mg total)
  • 12 weeks ≈ 4 vials (~18.2 mg total)
  • 16 weeks ≈ 6 vials (~26.2 mg total)<br
  • Syringes:
  • Per week: 2 syringes (twice weekly)
  • 8 weeks: 16 syringes
  • 12 weeks: 24 syringes
  • 16 weeks: 32 syringes
  • Bacteriostatic Water (10 mL bottles): Use approximately 2.0 mL per vial for reconstitution.
  • 8 weeks (3 vials): 6 mL → 1 × 10 mL bottle
  • 12 weeks (4 vials): 8 mL → 1 × 10 mL bottle
  • 16 weeks (6 vials): 12 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each injection.
  • Per week: 4 swabs (2 per injection × 2 injections)
  • 8 weeks: 32 swabs → recommend 1 × 100-count box
  • 12 weeks: 48 swabs → recommend 1 × 100-count box
  • 16 weeks: 64 swabs → recommend 1 × 100-count box
  • Protocol Overview

Concise summary of the twice-weekly regimen.

  • Goal: Support sustained GH and IGF-1 elevation for research into GH-axis effects.
  • Schedule: Twice-weekly subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 300–1000 mcg per injection with gradual titration.
  • Reconstitution: 2.0 mL per 5 mg vial (2.5 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
  • Dosing Protocol

Suggested twice-weekly titration approach.

  • Start: 300 mcg per injection twice weekly; increase by approximately 250 mcg every 2 weeks as tolerated.
  • Target: 750–1000 mcg per injection by Weeks 5–12.
  • Frequency: Twice per week (subcutaneous), spaced 3–4 days apart.
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Consistent timing (e.g., evenings); rotate injection sites.
  • Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for 2–4 weeks; avoid freeze–thaw.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Important Notes
Practical considerations for consistency and tolerability.
  • Use new sterile syringes for each injection; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) weekly to reduce local irritation.
  • Gradual dose escalation minimizes gastrointestinal side effects such as nausea.
  • Document weekly dose, injection site, and any adverse effects to maintain consistency.
  • For maintenance doses requiring >1.0 mL, ensure you have appropriately sized syringes (3 mL).
  • How This Works
CJC-1295 DAC mimics endogenous GHRH, binding to GHRH receptors on pituitary somatotrophs to drive GH release. The DAC modification (albumin-binding moiety) keeps the GHRH analog circulating for days rather than minutes, extending the half-life to approximately 6–8 days. The resulting GH surge stimulates IGF-1 production (primarily in the liver); IGF-1 then mediates many growth and metabolic effects through JAK/STAT signaling pathways. Notably, pulsatile GH secretion persists even during continuous CJC-1295 stimulation, preserving physiological release patterns.
  • Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

  • Supports sustained elevation of GH and IGF-1 in a dose-dependent manner.
  • May promote increased lean body mass, reduced fat mass, and improved body composition consistent with GH/IGF-1 axis activation.
  • Enhanced protein synthesis and recovery potential through anabolic signaling.
  • Generally well tolerated in clinical studies; occasional mild injection-site reactions (redness, swelling) may occur.
  • Some individuals report transient flushing, headache, or water retention during initial titration.
  • Lifestyle Factors

Complementary strategies for best outcomes.

  • Pair with a balanced, protein-forward diet tailored to energy and recovery needs.
  • Combine resistance training and aerobic activity to reinforce GH-mediated adaptations.
  • Prioritize quality sleep (7–9 hours) as endogenous GH release peaks during deep sleep.
  • Manage stress to support hormonal balance and adherence.
  • Injection Technique
General subcutaneous guidance from clinical best‑practice resources
  • Clean the vial stopper and skin with alcohol; allow to air dry completely.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
  • Do not aspirate for subcutaneous injections; inject slowly and steadily.
  • Hold for 5–10 seconds before withdrawing the needle to ensure complete delivery.
  • Rotate sites systematically (abdomen, thighs, upper arms) each week to avoid lipohypertrophy.
  • Recommended Source
We recommend Vitality Labs Blueprint Peptides for high-purity CJC-1295 DAC (5 mg).

Why Vitality Labs Blueprint Peptides?

  • High-purity, third-party-tested lots with batch COAs.
  • Consistent, ISO-aligned handling and documentation.
  • Reliable fulfillment to maintain cold-chain integrity.
Contact on Telegram
  • Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

  • References

J Clin Endocrinol Metab (2006)

— Teichman SL et al. Prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults.
More Info

J Clin Endocrinol Metab (2006)

— Ionescu M et al. Pulsatile GH secretion persists during continuous CJC-1295 stimulation

More Info

Am J Physiol Endocrinol Metab (2006)

— Alba M et al. Once-daily CJC-1295 normalizes growth in GHRH knockout mouse

More Info

StatPearls (NCBI Bookshelf)

Brinkman JE et al. Physiology, Growth Hormone

More Info

CDC Pink Book (Chapter 6)

— Vaccine administration: subcutaneous route (angle/site; no aspiration)

More Info

Johns Hopkins Arthritis Center

How to give a subcutaneous injection (patient guidance)

More Info

StatPearls (NCBI Bookshelf)

Regular Insulin: subcutaneous administration and site rotation

More Info

Immunize Canada

How to Vaccinate: Best Practices (subcutaneous injection technique)

More Info

Postgrad Med J (2006)

— Ayuk J, Sheppard MC. Growth hormone and its disorders

More Info

Vitality Lab Peptides

— CJC-1295 DAC (5 mg) product page (quality and batch documentation)

More Info